
- <Centre d'Information et de documentation du CRA Rhône-Alpes
- CRA
- Informations pratiques
-
Adresse
Centre d'information et de documentation
Horaires
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexLundi au Vendredi
Contact
9h00-12h00 13h30-16h00Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Adresse
Résultat de la recherche
1 recherche sur le mot-clé 'Cognitive tests'
Visionner les documents numériques
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche
Faire une suggestionAssessment of Cognitive Outcome Measures in Teenagers with 15q13.3 Microdeletion Syndrome / Emeline CRUTCHER in Journal of Autism and Developmental Disorders, 46-4 (April 2016)
![]()
[article]
Titre : Assessment of Cognitive Outcome Measures in Teenagers with 15q13.3 Microdeletion Syndrome Type de document : texte imprimé Auteurs : Emeline CRUTCHER, Auteur ; May ALI, Auteur ; John HARRISON, Auteur ; Judit SOVAGO, Auteur ; Baltazar GOMEZ-MANCILLA, Auteur ; Christian P. SCHAAF, Auteur Article en page(s) : p.1455-1463 Langues : Anglais (eng) Mots-clés : Neuropsychiatric disease Autism Intellectual disability Cognitive tests Cognitive function Index. décimale : PER Périodiques Résumé : 15q13.3 microdeletion syndrome causes a spectrum of cognitive disorders, including intellectual disability and autism. We aimed to determine if any or all of three cognitive testing systems (the KiTAP, CogState, and Stanford–Binet) are suitable for assessment of cognitive function in affected individuals. These three tests were administered to ten individuals with 15q13.3 microdeletion syndrome (14–18 years of age), and the results were analyzed to determine feasibility of use, potential for improvement, and internal consistency. It was determined that the KiTAP, CogState, and Stanford–Binet are valid tests of cognitive function in 15q13.3 microdeletion patients. Therefore, these tests may be considered for use as objective outcome measures in future clinical trials, assessing change in cognitive function over a period of pharmacological treatment. En ligne : http://dx.doi.org/10.1007/s10803-015-2694-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=284
in Journal of Autism and Developmental Disorders > 46-4 (April 2016) . - p.1455-1463[article] Assessment of Cognitive Outcome Measures in Teenagers with 15q13.3 Microdeletion Syndrome [texte imprimé] / Emeline CRUTCHER, Auteur ; May ALI, Auteur ; John HARRISON, Auteur ; Judit SOVAGO, Auteur ; Baltazar GOMEZ-MANCILLA, Auteur ; Christian P. SCHAAF, Auteur . - p.1455-1463.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 46-4 (April 2016) . - p.1455-1463
Mots-clés : Neuropsychiatric disease Autism Intellectual disability Cognitive tests Cognitive function Index. décimale : PER Périodiques Résumé : 15q13.3 microdeletion syndrome causes a spectrum of cognitive disorders, including intellectual disability and autism. We aimed to determine if any or all of three cognitive testing systems (the KiTAP, CogState, and Stanford–Binet) are suitable for assessment of cognitive function in affected individuals. These three tests were administered to ten individuals with 15q13.3 microdeletion syndrome (14–18 years of age), and the results were analyzed to determine feasibility of use, potential for improvement, and internal consistency. It was determined that the KiTAP, CogState, and Stanford–Binet are valid tests of cognitive function in 15q13.3 microdeletion patients. Therefore, these tests may be considered for use as objective outcome measures in future clinical trials, assessing change in cognitive function over a period of pharmacological treatment. En ligne : http://dx.doi.org/10.1007/s10803-015-2694-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=284

